{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:51:59Z","timestamp":1790297519289,"version":"4.1.0"},"reference-count":161,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Breast cancer (BC) is one of the leading causes of death from cancer in women; second only to lung cancer. Tamoxifen (TAM) is a hydrophobic anticancer agent and a selective estrogen modulator (SERM), approved by the FDA for hormone therapy of BC. Despite having striking efficacy in BC therapy, concerns regarding the dose-dependent carcinogenicity of TAM still persist, restricting its therapeutic applications. Nanotechnology has emerged as one of the most important strategies to solve the issue of TAM toxicity, owing to the ability of nano-enabled-formulations to deliver smaller concentrations of TAM to cancer cells, over a longer period of time. Various TAM-containing-nanosystems have been successfully fabricated to selectively deliver TAM to specific molecular targets found on tumour membranes, reducing unwanted toxic effects. This review begins with an outline of breast cancer, the current treatment options and a history of how TAM has been used as a combatant of BC. A detailed discussion of various nanoformulation strategies used to deliver lower doses of TAM selectively to breast tumours will then follow. Finally, a commentary on future perspectives of TAM being employed as a targeting vector, to guide the delivery of other therapeutic and diagnostic agents selectively to breast tumours will be presented.<\/jats:p>","DOI":"10.3390\/molecules25051182","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T09:26:41Z","timestamp":1583486801000},"page":"1182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-9118","authenticated-orcid":false,"given":"Candace M.","family":"Day","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences, University of South Australia, Cancer Research Institute, North Terrace, 5000 Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-531X","authenticated-orcid":false,"given":"Shane M.","family":"Hickey","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences, University of South Australia, Cancer Research Institute, North Terrace, 5000 Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmei","family":"Song","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences, University of South Australia, Cancer Research Institute, North Terrace, 5000 Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E.","family":"Plush","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences, University of South Australia, Cancer Research Institute, North Terrace, 5000 Adelaide, SA, Australia"},{"name":"Future Industry Institute, University of South Australia, 5095 Mawson Lakes, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-2629","authenticated-orcid":false,"given":"Sanjay","family":"Garg","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences, University of South Australia, Cancer Research Institute, North Terrace, 5000 Adelaide, SA, Australia"},{"name":"Future Industry Institute, University of South Australia, 5095 Mawson Lakes, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Gene Funct. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer. J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ijc.20514","article-title":"Breast cancer mortality patterns and time trends in 10 new EU member states: Mortality declining in young women, but still increasing in the elderly","volume":"112","author":"Tyczynski","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_4","unstructured":"(2020, February 01). Breast Cancer in Australia Statistics, Available online: www.breast-cancer.canceraustralia.gov.au\/statistics."},{"key":"ref_5","first-page":"51","article-title":"Management of Benign Breast Disease","volume":"Volume 2015","author":"Dixon","year":"2014","journal-title":"Breast Disease"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2231-4040.72251","article-title":"Various Types And Management Of Breast Cancer: An Overview","volume":"1","author":"Sharma","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_7","unstructured":"Cancer Australia (2020, February 01). Tests for Breast Cancer, Available online: www.breast-cancer.canceraustralia.gov.au\/diagnosis\/tests."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ijrobp.2015.12.020","article-title":"Distance to Radiation Facility and Treatment Choice in Early-Stage Breast Cancer","volume":"94","author":"Acharya","year":"2016","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sun, L., Legood, R., Dos-Santos-Silva, I., Gaiha, S., and Sadique, Z. (2018). Global treatment costs of breast cancer by stage: A systematic review. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207993"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jama.2013.5525","article-title":"Chemotherapy","volume":"310","author":"Sugerman","year":"2013","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/S0140-6736(17)31662-8","article-title":"Breast cancer targeted therapy: Successes and challenges","volume":"389","author":"Lancet","year":"2017","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1172\/JCI57152","article-title":"Targeted therapies for breast cancer","volume":"121","author":"Higgins","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/bmj.302.6771.272","article-title":"Side effects expected and experienced by women receiving chemotherapy for breast cancer","volume":"302","author":"Tierney","year":"1991","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hung, M.-H., Liu, C.-J., Teng, C.-J., Hu, Y.-W., Yeh, C.-M., Chen, S.-C., Chien, S.-H., Hung, Y.-P., Shen, C.-C., and Chen, T.-J. (2016). Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148597"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1517\/13543776.2013.805206","article-title":"Estrogen receptor ligands: A patent review update","volume":"23","author":"Paterni","year":"2013","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.mce.2013.08.005","article-title":"Estrogen receptor beta in breast cancer","volume":"382","author":"Zhao","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/cas.12613","article-title":"Clinical significance of estrogen receptor \u03b2 in breast and prostate cancer from biological aspects","volume":"106","author":"Omoto","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2217\/fon.14.110","article-title":"Estrogen and progesterone receptors in breast cancer","volume":"10","author":"Yip","year":"2014","journal-title":"Futur. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W","article-title":"Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study","volume":"89","author":"Elledge","year":"2000","journal-title":"Int. J. Cancer."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11060-017-2717-0","article-title":"Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis","volume":"137","author":"Jung","year":"2017","journal-title":"J. Neuro-Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mds286","article-title":"Human epidermal growth factor receptor-2-positive breast cancer: Does estrogen receptor status define two distinct subtypes?","volume":"24","author":"Winer","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Buonomo, O.C., Caredda, E., Portarena, I., Vanni, G., Orlandi, A., Bagni, C., Petrella, G., Palombi, L., and Orsaria, P. (2017). New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184680"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.amjsurg.2013.07.014","article-title":"Biology of the estrogen receptor, GPR30, in triple negative breast cancer","volume":"206","author":"Steiman","year":"2013","journal-title":"Am. J. Surg."},{"key":"ref_25","first-page":"923","article-title":"Tamoxifen: Molecular basis of use in cancer treatment and prevention","volume":"5","author":"Wiseman","year":"1996","journal-title":"Gen. Pharmacol."},{"key":"ref_26","first-page":"291","article-title":"Identification of isomers of a substituted triarylethylene: The crystal structure of 1-p-(2-dimethylaminoethoxyphenyl)-1,2-cis-diphenylbut-1-ene hydrobromide","volume":"1","author":"Kilbourn","year":"1968","journal-title":"Chem. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/212087a0","article-title":"Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes","volume":"212","author":"Harper","year":"1966","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/jrf.0.0130101","article-title":"A New Derivative Of Triphenylethylene: Effect On Implantation And Mode Of Action In Rats","volume":"13","author":"Harper","year":"1967","journal-title":"Reproduction"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1677\/joe.0.0370083","article-title":"Mode of Action of I.C.I. 46,474 in Preventing Implantation in Rats","volume":"37","author":"Harper","year":"1967","journal-title":"J. Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.1.5741.152","article-title":"New Synthetic Agent for the Induction of Ovulation: Preliminary Trials in Women","volume":"1","author":"Klopper","year":"1971","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1471-0528.1973.tb11230.x","article-title":"The Induction Of Ovulation by Tamoxifen","volume":"80","author":"Williamson","year":"1973","journal-title":"BJOG: Int. J. Obstet. Gynaecol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45695","DOI":"10.1074\/jbc.M208092200","article-title":"Estrogen Receptor-dependent and Estrogen Receptor-independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-induced Programmed Cell Death","volume":"277","author":"Obrero","year":"2002","journal-title":"J. Boil. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0163-7258(84)90043-3","article-title":"The pharmacology and clinical uses of tamoxifen","volume":"25","author":"Furr","year":"1984","journal-title":"Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/256592a0","article-title":"Oestrogen-responsive human breast cancer in long term tissue culture","volume":"256","author":"Lippman","year":"1975","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF02307030","article-title":"Effects of tamoxifen on growth and apoptosis of oestrogen-dependent and -independent human breast cancer cells","volume":"2","author":"Perry","year":"1995","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","first-page":"31","article-title":"Tamoxifen Goes Forward Alone","volume":"Volume 2013","author":"Maximov","year":"2013","journal-title":"Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/or.2014.3190","article-title":"Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)","volume":"32","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01806795","article-title":"Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial","volume":"7","author":"DeLozier","year":"1986","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01806042","article-title":"Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study","volume":"4","author":"Tormey","year":"1984","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01807370","article-title":"Long-term adjuvant tamoxifen study: Clinical update","volume":"9","author":"Tormey","year":"1987","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"The Scottish Trial (1987). Adjuvant tamoxifen in the management of operable breast cancer: Breast cancer trials committee Lancet. Lancet, 2, 171\u2013175.","DOI":"10.1016\/S0140-6736(87)90762-8"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/93.6.456","article-title":"Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years","volume":"93","author":"Stewart","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.1980.tb10912.x","article-title":"Evidence for the metabolic activation of non-steroidal antioestrogens: A study of structure-activity relationships","volume":"71","author":"Allen","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Quirke, V.M. (2017). Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00620"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Maximov, P.Y., McDaniel, R.E., and Jordan, V.C. (2013). Carcinogenesis and Tamoxifen. Tamoxifen: Pioneering Medicine in Breast Cancer, Springer.","DOI":"10.1007\/978-3-0348-0664-0"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(94)90747-1","article-title":"Gynaecological monitoring during tamoxifen therapy","volume":"344","author":"Bissett","year":"1994","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","article-title":"High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients","volume":"11","author":"Magriples","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/carcin\/20.7.1153","article-title":"The tamoxifen dilemma","volume":"20","author":"White","year":"1999","journal-title":"Carcinogenesis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/tde-2016-0083","article-title":"Polymeric micelles: A promising tool for tamoxifen delivery in cancer?","volume":"8","author":"Jena","year":"2017","journal-title":"Ther. Deliv."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Day, C.M., Parikh, A., Song, Y., and Garg, S. (2018). Nanotechnology and Nature\u2019s Miracle Compound: Curcumin. NanoNutraceuticals, Taylor & Francis.","DOI":"10.1201\/9781351138949-12"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12253-013-9740-z","article-title":"Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients","volume":"20","author":"Xuan","year":"2014","journal-title":"Pathol. Oncol. Res."},{"key":"ref_54","first-page":"742","article-title":"Progress in Nanomedicine: Approved and Investigational Nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P T Peer-Rev. J. Formul. Manag."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1039\/C6CS00592F","article-title":"Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment","volume":"46","author":"Dai","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_56","first-page":"1","article-title":"Nanocarriers for Diagnosis and Targeting of Breast Cancer","volume":"2013","author":"Sharma","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: Myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and Challenges of Liposome Assisted Drug Delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3797\/scipharm.0911-11","article-title":"Tamoxifen Citrate Encapsulated Sustained Release Liposomes: Preparation and Evaluation of Physicochemical Properties","volume":"78","author":"Layek","year":"2010","journal-title":"Sci. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12951-016-0163-3","article-title":"Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex","volume":"14","author":"Lin","year":"2016","journal-title":"J. Nanobiotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2011.10.056","article-title":"Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases","volume":"422","author":"Cosco","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_62","first-page":"271","article-title":"Formulation and characterization of tamoxifen loaded stealth liposomes for breast cancer","volume":"5","author":"Deepak","year":"2013","journal-title":"Int. J. Drug Dev. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/08982100802518574","article-title":"Studies on tamoxifen encapsulated in lipid vesicles: Effect on the growth of human breast cancer MCF-7 cells","volume":"19","author":"Bhatia","year":"2009","journal-title":"J. Liposome Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.18433\/J3P88Z","article-title":"Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells","volume":"13","author":"Guo","year":"2010","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/08982104.2018.1502315","article-title":"Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment","volume":"29","author":"Jose","year":"2018","journal-title":"J. Liposome Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-323-46144-3.00007-6","article-title":"Interfacial engineering of nanoparticles for cancer therapeutics","volume":"2017","author":"Rana","year":"2017","journal-title":"Nanostruct. Cancer Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/17425240903380446","article-title":"Overcoming the barriers in micellar drug delivery: Loading efficiency, in vivostability, and micelle\u2013cell interaction","volume":"7","author":"Kim","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jconrel.2004.12.009","article-title":"Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery","volume":"103","author":"Soga","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/nl025604a","article-title":"Diacyllipid-Polymer Micelles as Nanocarriers for Poorly Soluble Anticancer Drugs","volume":"2","author":"Gao","year":"2002","journal-title":"Nano Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-3659(03)00217-7","article-title":"Micelles from polyethyleneglycol\/phosphatidylethanolamine conjugates for tumour drug delivery","volume":"91","author":"Lukyanov","year":"2003","journal-title":"J. Control. Release."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"53351","DOI":"10.1039\/C6RA10874A","article-title":"Enhanced efficacy and a better pharmacokinetic profile of tamoxifen employing polymeric micelles","volume":"6","author":"Yadav","year":"2016","journal-title":"RSC Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.carbpol.2016.06.078","article-title":"Polymeric micelles of amphiphilic graft copolymer of \u03b1-tocopherol succinate-g-carboxymethyl chitosan for tamoxifen delivery: Synthesis, characterization and in vivo pharmacokinetic study","volume":"151","author":"Jena","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ijbiomac.2017.05.016","article-title":"Chitosan-palmitic acid based polymeric micelles as promising carrier for circumventing pharmacokinetic and drug delivery concerns of tamoxifen","volume":"102","author":"Thotakura","year":"2017","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijbiomac.2016.08.080","article-title":"Chitosan-modified PLGA polymeric nanocarriers with better delivery potential for tamoxifen","volume":"93","author":"Thakur","year":"2016","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_75","first-page":"232","article-title":"Swelling-controlled Drug Delivery Systems","volume":"Volume 2018","author":"Day","year":"2018","journal-title":"Biomaterials Science Series"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Agudelo, D., Sanyakamdhorn, S., Nafisi, S., and Tajmir-Riahi, H.A. (2013). Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060250"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.2147\/IJN.S63535","article-title":"Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy","volume":"9","author":"Mukherjee","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0885328216670561","article-title":"Tamoxifen citrate-loaded poly(d,l) lactic acid nanoparticles: Evaluation for their anticancer activity in vitro and in vivo","volume":"31","author":"Ravikumara","year":"2016","journal-title":"J. Biomater. Appl."},{"key":"ref_79","first-page":"1","article-title":"Tamoxifen-loaded solid lipid nanoparticles-induced apoptosis in breast cancer cell lines","volume":"11","author":"Abbasalipourkabir","year":"2015","journal-title":"J. Exp. Nanosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejps.2018.04.040","article-title":"Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer","volume":"120","author":"Eskiler","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1208\/s12249-017-0851-9","article-title":"Improved Oral Bioavailability, Therapeutic Efficacy, and Reduced Toxicity of Tamoxifen-Loaded Liquid Crystalline Nanoparticles","volume":"19","author":"Jain","year":"2017","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_82","first-page":"35011","article-title":"Biopolymer mediated nanoparticles synthesized from Adenia hondala for enhanced tamoxifen drug delivery in breast cancer cell line","volume":"8","author":"Pradeepa","year":"2017","journal-title":"ANSN"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s10904-017-0758-7","article-title":"Anticancer Activity of Tamoxifen Loaded Tyrosine Decorated Biocompatible Fe3O4 Magnetic Nanoparticles Against Breast Cancer Cell Lines","volume":"28","author":"Nosrati","year":"2017","journal-title":"J. Inorg. Organomet. Polym. Mater."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural Basis of the Drug-binding Specificity of Human Serum Albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Boil."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0006-2952(02)01074-2","article-title":"Predicting plasma protein binding of drugs: A new approach","volume":"64","author":"Kratochwil","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1385\/CBB:45:2:203","article-title":"An overview of drug binding to human serum albumin: Protein folding and unfolding","volume":"45","author":"Diamantoglou","year":"2006","journal-title":"Cell Biochem. Biophys."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jphotobiol.2015.09.008","article-title":"Transporting testosterone and its dimers by serum proteins","volume":"153","author":"Chanphai","year":"2015","journal-title":"J. Photochem. Photobiol. B Boil."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1021\/jp9115996","article-title":"Resveratrol, Genistein, and Curcumin Bind Bovine Serum Albumin","volume":"114","author":"Bourassa","year":"2010","journal-title":"J. Phys. Chem. B"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/jp910077h","article-title":"Study on the Interaction of Cationic Lipids with Bovine Serum Albumin","volume":"114","author":"Charbonneau","year":"2010","journal-title":"J. Phys. Chem. B"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijbiomac.2006.11.005","article-title":"Retinol and retinoic acid bind human serum albumin: Stability and structural features","volume":"40","author":"Ragi","year":"2007","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jpba.2008.11.035","article-title":"Study of curcumin and genistein interactions with human serum albumin","volume":"49","author":"Mandeville","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Akdo\u011fan, Y., Reichenwallner, J., and Hinderberger, D. (2012). Evidence for Water-Tuned Structural Differences in Proteins: An Approach Emphasizing Variations in Local Hydrophilicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045681"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbm.a.34051","article-title":"Tamoxifen-loaded thiolated alginate-albumin nanoparticles as antitumoral drug delivery systems","volume":"100","author":"Martinez","year":"2012","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1016\/j.ejmech.2011.07.005","article-title":"Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin","volume":"46","author":"Bourassa","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jddst.2017.06.007","article-title":"The synthesis of tamoxifen-loaded albumin nanoparticles by homogenizers: Optimization and in vitro characterization","volume":"41","author":"Safavi","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Akim, A.M., Tung, E.E., Chong, P.P., Hamzah, M.Y., and Dahlan, K.Z.M. (2013). Nanoparticle-Encapsulated Tamoxifen Inducing Cytotoxic Effect on Mcf-7 Breast Cancer Cell Lines. 4th Latin American Congress on Biomedical Engineering 2007, Bioengineering Solutions for Latin America Health, Springer.","DOI":"10.1007\/978-3-642-32183-2_58"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Othayoth, R., Karthik, V., and Kumar, K.S. (2013, January 24\u201326). Development and characterization of chitosan-pluronic nanoparticles for tamoxifen delivery and cytotoxicity to MCF-7 cells. Proceedings of the International Conference on Advanced Nanomaterials & Emerging Engineering Technologies, Chennai, India.","DOI":"10.1109\/ICANMEET.2013.6609328"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.colsurfb.2013.05.018","article-title":"pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells","volume":"111","author":"Vivek","year":"2013","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"ref_99","first-page":"587604","article-title":"Poly(amidoamine)-Cholesterol Conjugate Nanoparticles Obtained by Electrospraying as Novel Tamoxifen Delivery System","volume":"2011","author":"Roberta","year":"2011","journal-title":"J. Drug Deliv."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chauhan, D., and Srivastava, R. (2015, January 15\u201318). Synthesis and characterization of gold encapsulated and tamoxifen loaded PLGA nanoparticles for breast cancer theranostics. Proceedings of the 2015 9th IEEE International Conference on Nano\/Molecular Medicine & Engineering (NANOMED), Honolulu, HI, USA.","DOI":"10.1109\/NANOMED.2015.7492510"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijbiomac.2011.05.020","article-title":"Controlled release of tamoxifen citrate encapsulated in cross-linked guar gum nanoparticles","volume":"49","author":"Sarmah","year":"2011","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Shenoy, D.B., Chawla, J.S., and Amiji, M.M. (2004). Biodegradable Polymeric Nanoparticles for Tumor-Selective Tamoxifen Delivery: In Vitro and in Vivo Studies. Proceedings of the MRS Proceedings, Cambridge University Press.","DOI":"10.1557\/PROC-845-AA5.49"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1021\/mp400311j","article-title":"Co-encapsulation of Tsame for 100amoxifen and Quercetin in Polymeric Nanoparticles: Implications on Oral Bioavailability, Antitumor Efficacy, and Drug-Induced Toxicity","volume":"10","author":"Jain","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1166\/jnn.2016.10651","article-title":"Development of Novel Polymer-Lipid Hybrid Nanoparticles of Tamoxifen: In Vitro and In Vivo Evaluation","volume":"16","author":"Varthya","year":"2016","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_105","first-page":"187","article-title":"Cytotoxic Activities of Silver Nanoparticles and Silver Ions in Parent and Tamoxifen-Resistant T47D Human Breast Cancer Cells and Their Combination Effects with Tamoxifen against Resistant Cells","volume":"2","author":"Ostad","year":"2010","journal-title":"Avicenna J. Med Biotechnol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.colsurfb.2013.01.051","article-title":"Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer","volume":"106","author":"Majd","year":"2013","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/187221013804484827","article-title":"Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting","volume":"7","author":"Fang","year":"2013","journal-title":"Recent Patents Nanotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Beh, C.Y., Abdullah, R., Selvarajah, G.T., Yazan, L.S., Omar, A.R., Foong, J.N., How, C.W., and Foo, J.B. (2019). Enhanced anti-mammary gland cancer activities of tamoxifen-loaded erythropoietin-coated drug delivery system. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219285"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.colsurfb.2013.08.009","article-title":"Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: Characterization, stability assessment and cytotoxicity","volume":"112","author":"How","year":"2013","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1166\/asl.2014.5541","article-title":"Preparation and Characterization of Nanosuspension of Tamoxifen Citrate for Intra-Venous Administration in Drug Resistant Breast Cancer Cells","volume":"20","author":"Talat","year":"2014","journal-title":"Adv. Sci. Lett."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/mp700091j","article-title":"A Nanoemulsion Formulation of Tamoxifen Increases Its Efficacy in a Breast Cancer Cell Line","volume":"5","author":"Tagne","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-1978-24702","article-title":"\u201cCascade\u201d- and \u201cNonskid-Chain-like\u201d Syntheses of Molecular Cavity Topologies","volume":"1978","author":"Buhleier","year":"1978","journal-title":"Synthesis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"24808","DOI":"10.1039\/C6RA02391F","article-title":"Hydrophobic myristic acid modified PAMAM dendrimers augment the delivery of tamoxifen to breast cancer cells","volume":"6","author":"Matai","year":"2016","journal-title":"RSC Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0142-9612(02)00445-3","article-title":"In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis","volume":"24","author":"Fischer","year":"2003","journal-title":"Biomaterials"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/mthe.2002.0523","article-title":"Fr New Basic Membrane-Destabilizing Peptides for Plasmid-Based Gene Delivery in Vitro and in Vivo","volume":"5","author":"Rittner","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10348","DOI":"10.1021\/la050629l","article-title":"Lipid Bilayer Disruption by Polycationic Polymers: The Roles of Size and Chemical Functional Group","volume":"21","author":"Mecke","year":"2005","journal-title":"Langmuir"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"10044","DOI":"10.1021\/ja048548j","article-title":"Cytotoxicity, Hemolysis, and Acute in Vivo Toxicity of Dendrimers Based on Melamine, Candidate Vehicles for Drug Delivery","volume":"126","author":"Chen","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bioelechem.2003.09.023","article-title":"Influence of PAMAM dendrimers on human red blood cells","volume":"63","author":"Bryszewska","year":"2004","journal-title":"Bioelectrochemistry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijpharm.2010.04.027","article-title":"Dendrimer toxicity: Let\u2019s meet the challenge","volume":"394","author":"Jain","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_120","first-page":"1","article-title":"Evaluation of host\u2013guest system to enhance the tamoxifen efficiency","volume":"45","author":"Majd","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8417016","article-title":"Fabrication, Characterization, and Functionalization of Single-Walled Carbon Nanotube Conjugated with Tamoxifen and Its Anticancer Potential against Human Breast Cancer Cells","volume":"2018","author":"Oskoueian","year":"2018","journal-title":"J. Nanomater."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/IJN.S37348","article-title":"Nanodiamonds as novel nanomaterials for biomedical applications: Drug delivery and imaging systems","volume":"8","author":"Badea","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7150\/thno.3627","article-title":"The Biocompatibility of Nanodiamonds and Their Application in Drug Delivery Systems","volume":"2","author":"Zhu","year":"2012","journal-title":"Theranostics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/685081","article-title":"Synthesis, Properties, and Applications of Low-Dimensional Carbon-Related Nanomaterials","volume":"2011","author":"Mostofizadeh","year":"2011","journal-title":"J. Nanomater."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"9648","DOI":"10.1016\/j.biomaterials.2013.08.056","article-title":"Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer","volume":"34","author":"Xiao","year":"2013","journal-title":"Biomater."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ctrv.2013.09.010","article-title":"The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer","volume":"40","author":"Ribelles","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijbiomac.2014.09.022","article-title":"Breast anticancer drug tamoxifen and its metabolites bind tRNA at multiple sites","volume":"72","author":"Bourassa","year":"2015","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_128","first-page":"1","article-title":"Construction of a Nanodiamond\u2013Tamoxifen Complex as a Breast Cancer Drug Delivery Vehicle","volume":"2016","year":"2016","journal-title":"J. Nanomater."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3109\/10837450.2011.649855","article-title":"Cyclodextrin-based nanosponges: Effective nanocarrier for Tamoxifen delivery","volume":"18","author":"Torne","year":"2012","journal-title":"Pharm. Dev. Technol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2009.07.015","article-title":"Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization","volume":"380","author":"Elnaggar","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/2210303106666161129163850","article-title":"Sustained Delivery of Tamoxifen from a Nanofluidic Delivery Platform","volume":"6","author":"Ballerini","year":"2017","journal-title":"Drug Deliv. Lett."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.biopha.2014.03.004","article-title":"Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: In vitro and in vivo evaluation","volume":"68","author":"Jain","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/bc9002212","article-title":"Tamoxifen\u2212Poly(ethylene glycol)\u2212Thiol Gold Nanoparticle Conjugates: Enhanced Potency and Selective Delivery for Breast Cancer Treatment","volume":"20","author":"Dreaden","year":"2009","journal-title":"Bioconjugate Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.carbpol.2019.05.067","article-title":"Review of polysaccharide particle-based functional drug delivery","volume":"221","author":"Barclay","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1016\/j.bmcl.2016.09.028","article-title":"A new selective fluorescent probe based on tamoxifen","volume":"26","author":"Ho","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1021\/acs.jmedchem.7b00682","article-title":"A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy","volume":"60","author":"Zhang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1021\/bc900461h","article-title":"Synthesis and Characterization of Fluorescent 4-Hydroxytamoxifen Conjugates with Unique Antiestrogenic Properties","volume":"21","author":"Rickert","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1002\/wnan.1416","article-title":"Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials","volume":"9","author":"Caster","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1021\/nn301922x","article-title":"In Vitro\u2013In VivoTranslation of Lipid Nanoparticles for Hepatocellular siRNA Delivery","volume":"6","author":"Whitehead","year":"2012","journal-title":"ACS Nano"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2230-973X.160844","article-title":"Mesoporous silica nanoparticles in target drug delivery system: A review","volume":"5","author":"Bharti","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1114397","article-title":"Toxic Potential of Materials at the Nanolevel","volume":"311","author":"Nel","year":"2006","journal-title":"Science"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.pharmtox.010909.105819","article-title":"Close Encounters of the Small Kind: Adverse Effects of Man-Made Materials Interfacing with the Nano-Cosmos of Biological Systems","volume":"50","author":"Shvedova","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfq268","article-title":"Cell Death Mechanisms and Their Implications in Toxicology","volume":"119","author":"Orrenius","year":"2010","journal-title":"Toxicol. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1039\/c0jm01390k","article-title":"Impact of different PEGylation patterns on the long-term bio-stability of colloidal mesoporous silica nanoparticles","volume":"20","author":"Cauda","year":"2010","journal-title":"J. Mater. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cej.2007.07.088","article-title":"Synthesis and stealthing study of bare and PEGylated silica micro- and nanoparticles as potential drug-delivery vectors","volume":"137","author":"Moros","year":"2008","journal-title":"Chem. Eng. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/smll.201001459","article-title":"In vivo Biodistribution and Urinary Excretion of Mesoporous Silica Nanoparticles: Effects of Particle Size and PEGylation","volume":"7","author":"He","year":"2010","journal-title":"Small"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/ja2084338","article-title":"Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake","volume":"134","author":"Walkey","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/mp400703d","article-title":"Evading Immune Cell Uptake and Clearance Requires PEG Grafting at Densities Substantially Exceeding the Minimum for Brush Conformation","volume":"11","author":"Yang","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: An open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_157","first-page":"1","article-title":"Use of Targeted Liposome-based Chemotherapeutics to Treat Breast Cancer","volume":"9","author":"Khan","year":"2015","journal-title":"Breast Cancer Basic Clin. Res."},{"key":"ref_158","first-page":"1","article-title":"CHAPTER 1. Fundamentals of Stimuli-responsive Drug and Gene Delivery Systems","volume":"2018","author":"Torchilin","year":"2018","journal-title":"Biomater. Sci. Ser."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Raza, A., Rasheed, T., Nabeel, F., Hayat, U., Bilal, M., and Iqbal, H.M. (2019). Endogenous and Exogenous Stimuli-Responsive Drug Delivery Systems for Programmed Site-Specific Release. Molecules, 24.","DOI":"10.3390\/molecules24061117"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e1803262","DOI":"10.1002\/smll.201803262","article-title":"Tumor-pH-Responsive Dissociable Albumin-Tamoxifen Nanocomplexes Enabling Efficient Tumor Penetration and Hypoxia Relief for Enhanced Cancer Photodynamic Therapy","volume":"14","author":"Yang","year":"2018","journal-title":"Small"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.2147\/OTT.S201421","article-title":"A temperature-sensitive phase-change hydrogel of tamoxifen achieves the long-acting antitumor activation on breast cancer cells","volume":"12","author":"Meng","year":"2019","journal-title":"Onco. Targets Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/5\/1182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:04:34Z","timestamp":1760173474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/5\/1182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":161,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["molecules25051182"],"URL":"https:\/\/doi.org\/10.3390\/molecules25051182","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}